vs
阿普塔集团（ATR）与科睿唯安（CLVT）财务数据对比。点击上方公司名可切换其他公司
阿普塔集团的季度营收约是科睿唯安的1.6倍（$962.7M vs $585.5M），阿普塔集团净利率更高（7.7% vs -6.9%，领先14.6%），阿普塔集团同比增速更快（13.5% vs -1.4%），阿普塔集团自由现金流更多（$96.9M vs $78.9M），过去两年阿普塔集团的营收复合增速更高（2.6% vs -5.1%）
阿普塔集团（AptarGroup, Inc.）是总部位于美国的全球性制造企业，主营消费品分配包装产品及药物给药装置的研发与生产，目前在全球18个国家设有生产运营基地，服务医药、快消等多领域客户。
科睿唯安是一家英美合资的上市分析服务企业，主要提供订阅制信息服务，覆盖文献计量、科学计量、商业与市场情报领域，同时为医药、生物科技行业提供专利、监管合规相关的竞争分析，也提供商标保护、域名与品牌保护服务，旗下Web of Science产品系列还负责计算学术期刊的影响因子。
ATR vs CLVT — 直观对比
营收规模更大
ATR
是对方的1.6倍
$585.5M
营收增速更快
ATR
高出14.9%
-1.4%
净利率更高
ATR
高出14.6%
-6.9%
自由现金流更多
ATR
多$18.0M
$78.9M
两年增速更快
ATR
近两年复合增速
-5.1%
损益表 — Q4 FY2025 vs Q1 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $962.7M | $585.5M |
| 净利润 | $74.3M | $-40.2M |
| 毛利率 | — | 67.2% |
| 营业利润率 | 11.0% | 5.2% |
| 净利率 | 7.7% | -6.9% |
| 营收同比 | 13.5% | -1.4% |
| 净利润同比 | -26.4% | 61.3% |
| 每股收益（稀释后） | $1.13 | $-0.06 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ATRCLVT
| Q1 26 | — | $585.5M | ||
| Q4 25 | $962.7M | $617.0M | ||
| Q3 25 | $961.1M | $623.1M | ||
| Q2 25 | $966.0M | $621.4M | ||
| Q1 25 | $887.3M | $593.7M | ||
| Q4 24 | $848.1M | $663.0M | ||
| Q3 24 | $909.3M | $622.2M | ||
| Q2 24 | $910.1M | $650.3M |
净利润ATRCLVT
| Q1 26 | — | $-40.2M | ||
| Q4 25 | $74.3M | $3.1M | ||
| Q3 25 | $127.9M | $-28.3M | ||
| Q2 25 | $111.7M | $-72.0M | ||
| Q1 25 | $78.8M | $-103.9M | ||
| Q4 24 | $100.9M | $-191.8M | ||
| Q3 24 | $100.0M | $-65.6M | ||
| Q2 24 | $90.5M | $-304.3M |
毛利率ATRCLVT
| Q1 26 | — | 67.2% | ||
| Q4 25 | — | 66.8% | ||
| Q3 25 | — | 65.0% | ||
| Q2 25 | — | 67.2% | ||
| Q1 25 | — | 65.1% | ||
| Q4 24 | — | 65.7% | ||
| Q3 24 | — | 66.2% | ||
| Q2 24 | — | 67.2% |
营业利润率ATRCLVT
| Q1 26 | — | 5.2% | ||
| Q4 25 | 11.0% | 6.7% | ||
| Q3 25 | 14.2% | 7.1% | ||
| Q2 25 | 14.9% | 1.1% | ||
| Q1 25 | 12.8% | -3.5% | ||
| Q4 24 | 14.2% | -9.4% | ||
| Q3 24 | 15.2% | 3.5% | ||
| Q2 24 | 13.8% | -36.9% |
净利率ATRCLVT
| Q1 26 | — | -6.9% | ||
| Q4 25 | 7.7% | 0.5% | ||
| Q3 25 | 13.3% | -4.5% | ||
| Q2 25 | 11.6% | -11.6% | ||
| Q1 25 | 8.9% | -17.5% | ||
| Q4 24 | 11.9% | -28.9% | ||
| Q3 24 | 11.0% | -10.5% | ||
| Q2 24 | 9.9% | -46.8% |
每股收益（稀释后）ATRCLVT
| Q1 26 | — | $-0.06 | ||
| Q4 25 | $1.13 | $0.00 | ||
| Q3 25 | $1.92 | $-0.04 | ||
| Q2 25 | $1.67 | $-0.11 | ||
| Q1 25 | $1.17 | $-0.15 | ||
| Q4 24 | $1.48 | $-0.27 | ||
| Q3 24 | $1.48 | $-0.09 | ||
| Q2 24 | $1.34 | $-0.46 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $409.5M | — |
| 总债务越低越好 | $1.1B | $4.3B |
| 股东权益账面价值 | $2.7B | $4.8B |
| 总资产 | $5.3B | $10.9B |
| 负债/权益比越低杠杆越低 | 0.43× | 0.89× |
8季度趋势，按日历期对齐
现金及短期投资ATRCLVT
| Q1 26 | — | — | ||
| Q4 25 | $409.5M | $329.2M | ||
| Q3 25 | $264.8M | $318.7M | ||
| Q2 25 | $169.8M | $362.6M | ||
| Q1 25 | $136.8M | $354.0M | ||
| Q4 24 | $226.2M | $295.2M | ||
| Q3 24 | $327.9M | $388.5M | ||
| Q2 24 | $223.9M | $376.4M |
总债务ATRCLVT
| Q1 26 | — | $4.3B | ||
| Q4 25 | $1.1B | $4.3B | ||
| Q3 25 | $546.0M | $4.4B | ||
| Q2 25 | $535.1M | $4.5B | ||
| Q1 25 | $561.2M | $4.5B | ||
| Q4 24 | $688.1M | $4.5B | ||
| Q3 24 | $822.7M | $4.6B | ||
| Q2 24 | $681.5M | $4.6B |
股东权益ATRCLVT
| Q1 26 | — | $4.8B | ||
| Q4 25 | $2.7B | $4.8B | ||
| Q3 25 | $2.8B | $4.9B | ||
| Q2 25 | $2.7B | $5.0B | ||
| Q1 25 | $2.5B | $5.0B | ||
| Q4 24 | $2.5B | $5.1B | ||
| Q3 24 | $2.5B | $5.5B | ||
| Q2 24 | $2.4B | $5.6B |
总资产ATRCLVT
| Q1 26 | — | $10.9B | ||
| Q4 25 | $5.3B | $11.1B | ||
| Q3 25 | $5.1B | $11.2B | ||
| Q2 25 | $4.9B | $11.4B | ||
| Q1 25 | $4.5B | $11.5B | ||
| Q4 24 | $4.4B | $11.5B | ||
| Q3 24 | $4.6B | $12.0B | ||
| Q2 24 | $4.5B | $12.1B |
负债/权益比ATRCLVT
| Q1 26 | — | 0.89× | ||
| Q4 25 | 0.43× | 0.89× | ||
| Q3 25 | 0.20× | 0.90× | ||
| Q2 25 | 0.20× | 0.90× | ||
| Q1 25 | 0.22× | 0.90× | ||
| Q4 24 | 0.28× | 0.88× | ||
| Q3 24 | 0.32× | 0.84× | ||
| Q2 24 | 0.28× | 0.83× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $183.7M | $134.7M |
| 自由现金流经营现金流 - 资本支出 | $96.9M | $78.9M |
| 自由现金流率自由现金流/营收 | 10.1% | 13.5% |
| 资本支出强度资本支出/营收 | 9.0% | 9.5% |
| 现金转化率经营现金流/净利润 | 2.47× | — |
| 过去12个月自由现金流最近4个季度 | $299.6M | $333.9M |
8季度趋势，按日历期对齐
经营现金流ATRCLVT
| Q1 26 | — | $134.7M | ||
| Q4 25 | $183.7M | $159.9M | ||
| Q3 25 | $177.6M | $181.1M | ||
| Q2 25 | $126.0M | $116.3M | ||
| Q1 25 | $82.7M | $171.2M | ||
| Q4 24 | $178.2M | $141.3M | ||
| Q3 24 | $229.3M | $202.9M | ||
| Q2 24 | $143.6M | $126.2M |
自由现金流ATRCLVT
| Q1 26 | — | $78.9M | ||
| Q4 25 | $96.9M | $89.2M | ||
| Q3 25 | $114.3M | $115.5M | ||
| Q2 25 | $62.5M | $50.3M | ||
| Q1 25 | $25.9M | $110.3M | ||
| Q4 24 | $112.2M | $59.1M | ||
| Q3 24 | $162.7M | $126.3M | ||
| Q2 24 | $75.4M | $60.3M |
自由现金流率ATRCLVT
| Q1 26 | — | 13.5% | ||
| Q4 25 | 10.1% | 14.5% | ||
| Q3 25 | 11.9% | 18.5% | ||
| Q2 25 | 6.5% | 8.1% | ||
| Q1 25 | 2.9% | 18.6% | ||
| Q4 24 | 13.2% | 8.9% | ||
| Q3 24 | 17.9% | 20.3% | ||
| Q2 24 | 8.3% | 9.3% |
资本支出强度ATRCLVT
| Q1 26 | — | 9.5% | ||
| Q4 25 | 9.0% | 11.5% | ||
| Q3 25 | 6.6% | 10.5% | ||
| Q2 25 | 6.6% | 10.6% | ||
| Q1 25 | 6.4% | 10.3% | ||
| Q4 24 | 7.8% | 12.4% | ||
| Q3 24 | 7.3% | 12.3% | ||
| Q2 24 | 7.5% | 10.1% |
现金转化率ATRCLVT
| Q1 26 | — | — | ||
| Q4 25 | 2.47× | 51.58× | ||
| Q3 25 | 1.39× | — | ||
| Q2 25 | 1.13× | — | ||
| Q1 25 | 1.05× | — | ||
| Q4 24 | 1.77× | — | ||
| Q3 24 | 2.29× | — | ||
| Q2 24 | 1.59× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ATR
| Pharma Segment | $833.1M | 87% |
| Other | $129.6M | 13% |
CLVT
| Subscription | $397.5M | 68% |
| Re-occurring | $108.6M | 19% |
| Transactional | $79.4M | 14% |
